Today: 28 June 2026
Browse Category

Biotechnology 19 August 2025 - 8 October 2025

AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025

AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025

Recursion Pharmaceuticals’ stock jumped 16% to $6.08 on October 8, 2025, after falling over 5% the previous day. The company uses AI to accelerate drug discovery and recently reported Q2 revenue of $19.2 million, up 33% year-over-year, but posted a net loss of $171.9 million. Recursion holds about $534 million in cash. Recent moves include acquiring Exscientia and cutting several pipeline programs.
8 October 2025
···
No-Revenue Biotech Soars 64,000% – Is Regencell (RGC) a Breakthrough or a Bubble?

No-Revenue Biotech Soars 64,000% – Is Regencell (RGC) a Breakthrough or a Bubble?

Regencell Bioscience shares soared over 64,000% in 2025, peaking at $83.60 before plunging 74% to around $17–18 by October, with a market cap near $8.5 billion. The stock jumped again in early October after S&P Global BMI Index inclusion and positive Phase II trial data showing a 37% improvement in ADHD/ASD symptoms. Regencell remains unprofitable with no revenue. Analysts maintain a “Strong Sell” rating.
7 October 2025
··
Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough – Inside the Stock Surge, Pipeline & Outlook (Oct 2025)

Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough – Inside the Stock Surge, Pipeline & Outlook (Oct 2025)

Spruce Biosciences shares soared over 1,300% after the FDA granted breakthrough therapy designation to its lead drug for Sanfilippo Syndrome Type B. Trading was repeatedly halted amid a flood of investor interest, including public backing from Martin Shkreli. The company, recently relisted on Nasdaq, faces ongoing financial strain with just $16.4 million in cash and no significant revenue.
7 October 2025
··
Tarsus Eyedrop Breakthrough Sends Stock Soaring: 10.9% Rally and Counting

Tarsus Eyedrop Breakthrough Sends Stock Soaring: 10.9% Rally and Counting

Tarsus (NASDAQ:TARS) surged 10.9% to $65.17 on Oct. 3, 2025, after reporting Q2 net product revenue of $102.7 million, up 152% year-over-year, driven by XDEMVY eyedrop sales. Shares have climbed 31% in the past month and 84% over the year. Wall Street consensus rates the stock a “Buy,” with average 12-month targets near $71. Losses are narrowing as sales rise and cash reserves remain strong.
3 October 2025
···
Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Cidara Therapeutics (CDTX) Stock Soars After $339M BARDA Flu-Drug Deal – Is CD388 the Next Big Flu-Fighter?

Cidara shares jumped 5.7% to $104.13 Friday morning, nearing a 52-week high after winning a BARDA award worth up to $339 million for its flu drug CD388. The stock is up over 200% year-to-date, with analysts raising price targets as high as $173. Cidara reported $516.9 million in cash and a Q2 net loss of $25.7 million. Short interest stands at 11.3% of float.
3 October 2025
··
Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

GRAL shares surged to $69.14 intraday on Oct 3, up nearly 6.8% and about 248% year-to-date. Market cap reached $2.3–2.5 billion, a 472% jump since mid-2024, despite ongoing losses and negative EPS. Wall Street consensus remains “Hold” with a $31.50 average price target, far below current levels. Investors await new PATHFINDER 2 trial data at ESMO Congress later this month.
3 October 2025
···
Sarepta Therapeutics Stock Skyrockets After FDA U-Turn – Gene Therapy Drama Explained

Sarepta Therapeutics Stock Skyrockets After FDA U-Turn – Gene Therapy Drama Explained

The FDA on July 28, 2025, cleared Elevidys gene therapy shipments for ambulatory patients after finding no link to a child’s death, while Sarepta added black-box liver warnings. Sarepta’s Q2 revenue jumped 68% to $611.1 million, but shares plunged 85% YTD before rebounding to $22.35 after the FDA decision. The EU’s CHMP issued a negative opinion on Elevidys, delaying European approval. Sarepta cut 36% of its workforce in July.
3 October 2025
··
Nebius (NBIS) Stock Rockets on $17B Microsoft AI Deal – Explosive Growth & Outlook Revealed

Biotech Boom: NBIS Surges After Microsoft‑NeoCloud AI Deal – Is a New Bull Market Ahead?

The Nasdaq Biotechnology Index closed at 5,007.41 on Oct. 2, up 2.61%, its highest in over a year. The index traded between 4,911.94 and 5,039.83 and has ranged from 3,568.35 to 5,039.83 over the past 52 weeks. Biotech stocks have been volatile amid U.S. drug-pricing reform uncertainty, but recent AI deals and low valuations have drawn buyers.
2 October 2025
····
Billion-Dollar AI Bets and Biotech Breakthroughs: Top Tech News (Sept 27–28, 2025)

Billion-Dollar AI Bets and Biotech Breakthroughs: Top Tech News (Sept 27–28, 2025)

Nvidia will invest up to $100 billion to build 10 gigawatts of AI data centers for OpenAI, with the first 1 GW due by late 2026. The US cybersecurity agency issued an emergency directive after hackers breached at least one federal agency via Cisco firewall flaws, affecting hundreds of devices. The FDA approved Eli Lilly’s new breast cancer drug Inluriyo. The SEC loosened ETF rules, opening the door for new crypto ETFs.
28 September 2025
·········
Scholar Rock (SRRK) Just Hit a Regulatory Speed Bump—But the Long‑Term Muscle‑Building Story Still Has Legs

Scholar Rock (SRRK) Just Hit a Regulatory Speed Bump—But the Long‑Term Muscle‑Building Story Still Has Legs

The FDA issued a Complete Response Letter for Scholar Rock’s apitegromab on Sept. 23, citing only manufacturing issues at a third-party Indiana plant. Shares fell but analysts, including BMO and Leerink, maintained bullish outlooks, expecting a quick resolution. The EMA review continues, with a possible EU launch in late 2026. Scholar Rock reported $295 million in cash as of June 30.
26 September 2025
··
PSTV ERUPTS: UnitedHealthcare Backs Plus Therapeutics’ CNS Cancer Test—Stock Pops, Analysts Cheer, and the Real Winners Could Be Patients

PSTV ERUPTS: UnitedHealthcare Backs Plus Therapeutics’ CNS Cancer Test—Stock Pops, Analysts Cheer, and the Real Winners Could Be Patients

Plus Therapeutics’ CNSide Diagnostics signed a national agreement with UnitedHealthcare to cover its CNSide tumor cell test, effective Sept. 15, potentially reaching over 51 million members. PSTV shares surged about 60% premarket on Sept. 25 after the news. CNSide’s Houston lab secured CLIA accreditation the prior week. Plus Therapeutics also received $1.9 million in non-dilutive funding from CPRIT on Sept. 22.
26 September 2025
···
uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

Gene Therapy Breakthrough: uniQure’s QURE Stock Skyrockets on Huntington’s Triumph

uniQure shares jumped over 150% on September 24, 2025, after its Huntington’s gene therapy slowed disease progression by 75% in a landmark trial. The company’s market value rose above $2.5 billion. uniQure plans to seek FDA approval in early 2026 and secured a $175 million credit facility to support commercialization. Cash reserves reached $377 million as of June 30, 2025.
24 September 2025
····
uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

uniQure reported its gene therapy AMT-130 slowed Huntington’s disease progression by 75% over three years in high-dose patients. Trading in QURE shares was halted on volatility; the stock jumped from $4.45 to the mid-teens. The company secured a $175 million loan to fund AMT-130’s potential launch. Wall Street analysts rate the stock “Buy,” with targets averaging $37–$40.
24 September 2025
···
Biting Back: How CRISPR-Edited Mice Could Stop the Lyme Disease Plague

Biting Back: How CRISPR-Edited Mice Could Stop the Lyme Disease Plague

Scientists plan to release thousands of CRISPR-edited, Lyme-immune mice on Nantucket, pending regulatory and community approval. The goal is to disrupt the Lyme disease cycle by making white-footed mice resistant, reducing infected ticks. About 15% of Nantucket residents have contracted Lyme, one of the nation’s highest rates. Residents will vote on the proposal amid ethical and ecological concerns.
23 September 2025
Inside Altos Labs: Jeff Bezos’s $3 Billion Bet to Reverse Aging

Inside Altos Labs: Jeff Bezos’s $3 Billion Bet to Reverse Aging

Altos Labs, a $3 billion biotech startup backed by Jeff Bezos, published a 2024 study showing partial cellular reprogramming extended lifespan and improved health in mice. The company, led by Hal Barron and Nobel laureate Shinya Yamanaka, focuses on rejuvenating cells to extend healthy years, not immortality. Altos faces competition from firms like Calico and Retro Biosciences in the fast-growing longevity sector.
20 September 2025
··
CRISPR ‘Prime Editing’ Breakthrough Cures Genetic Liver Disease in Mice

CRISPR ‘Prime Editing’ Breakthrough Cures Genetic Liver Disease in Mice

Scientists used CRISPR prime editing in live mice to correct a single DNA mutation in liver cells, curing a metabolic disease similar to phenylketonuria. Editing about 20% of hepatocytes reduced toxic phenylalanine levels to normal. The method rewrote the faulty gene without cutting DNA strands, using lipid nanoparticles and viral delivery for temporary editing.
15 September 2025
Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

The U.S. administration fired CDC Director Dr. Susan Monarez after she resisted Health Secretary Robert F. Kennedy Jr.’s directives; four senior CDC officials resigned in protest, citing risks to young Americans and pregnant women. U.S. regulators approved updated COVID-19 vaccines for fall, but limited routine access to adults 65+ and high-risk groups, excluding healthy under-65s.
28 August 2025
····
Obesity Pill Breakthrough, Gene Therapy Triumph & Billion-Dollar Psychedelic Bet – Global Biotech & Health Highlights (Aug 26–27, 2025)

Obesity Pill Breakthrough, Gene Therapy Triumph & Billion-Dollar Psychedelic Bet – Global Biotech & Health Highlights (Aug 26–27, 2025)

Eli Lilly’s oral weight-loss drug orforglipron cut body weight by up to 10.5% in a Phase 3 trial for obese diabetics, with all doses meeting primary endpoints over 72 weeks. The FDA granted full approval to Precigen’s Papzimeos, the first gene therapy for adult recurrent respiratory papillomatosis. AbbVie agreed to acquire a psychedelic-based depression drug from Gilgamesh Pharmaceuticals in a deal worth up to $1.2 billion.
27 August 2025
·····
Biotech Breakthroughs, Pharma Shakeups & Health Alerts – Global News Roundup (Aug 19–20, 2025)

Biotech Breakthroughs, Pharma Shakeups & Health Alerts – Global News Roundup (Aug 19–20, 2025)

CSL will cut up to 15% of its workforce and spin off its vaccine unit, targeting $500–550 million in annual savings. Medtronic agreed to add two board members and form new committees after Elliott Investment Management took a major stake. Merck KGaA and Skyhawk Therapeutics announced a neurological drug pact worth up to $2 billion. Pfizer, Bristol Myers Squibb, and Regeneron reported improved Q2 2025 earnings.
20 August 2025
·····
Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Genentech is ending its $2 billion cell therapy partnership with Adaptive Biotechnologies, citing cost-cutting but no safety issues. Kriya Therapeutics raised $313 million in Series D funding, one of the year’s largest biotech rounds. The FDA delayed Neurizon’s ALS drug trial review until October due to staffing shortages. Stealth BioTherapeutics has resubmitted its elamipretide application for Barth syndrome after two FDA rejections.
19 August 2025
····
1 … 16 17 18 19

Stock Market Today

  • Goldman Sachs Shares Pull Back 7% After 50% Annual Gain; Valuation Seen Slightly Overvalued
    June 28, 2026, 4:22 AM EDT. Goldman Sachs (GS) shares closed at $1,019.61 on June 28, down 7% over the past week but up 50.6% over the last year. Despite a strong three-year gain of 239.1%, the stock showed a recent pullback. Valuation analysis using an Excess Returns model indicates the stock is about 10.4% overvalued, with an intrinsic value estimated at $923.45 versus the current price. Investors are advised to carefully consider Price-to-Earnings (P/E) ratios and valuation models amid robust long-term gains and evolving market conditions before making new investment decisions.

Latest articles

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 28.06.2026

28 June 2026
LIVEMarkets rolling coverageStarted: June 28, 2026, 4:00 AM EDTUpdated: June 28, 2026, 4:30 AM EDT Goldman Sachs Shares Pull Back 7% After 50% Annual Gain; Valuation Seen Slightly Overvalued June 28, 2026, 4:22 AM EDT. Goldman Sachs (GS) shares closed at $1,019.61 on June 28, down 7% over the past week but up 50.6% over the last year. Despite a strong three-year gain of 239.1%, the stock showed a recent pullback. Valuation analysis using an Excess Returns model indicates the stock is about 10.4% overvalued, with an intrinsic value estimated at $923.45 versus the current price. Investors are advised to
Go toTop